Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia.
Epidemiology
Indigenous Australians
Liver cancer
Survival
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
09
02
2021
revised:
25
04
2021
accepted:
06
05
2021
entrez:
18
6
2021
pubmed:
19
6
2021
medline:
19
6
2021
Statut:
epublish
Résumé
Liver disease and hepatocellular carcinoma (HCC) are important contributors to the mortality gap between Indigenous and non-Indigenous Australians. However, there is a lack of population based high quality data assessing the differences in HCC epidemiology and outcomes according to Indigenous status. The aim of this study was therefore to perform a large epidemiological study of HCC investigating differences between Indigenous and non-Indigenous Australians with HCC. Study design was a retrospective cohort study. Data linkage methodology was used to link data from cancer registries with hospital separation summaries across three Australian jurisdictions during 2000-2017. Cumulative survival (Kaplan-Meier) and the differences in survival (Multivariable Cox-regression) by Indigenous status were assessed. A total of 229 Indigenous and 3587 non-Indigenous HCC cases were included in the analyses. Significant epidemiological differences identified for Indigenous HCC cases included younger age at onset, higher proportion of females, higher rurality, lower socioeconomic status, and higher comorbidity burden (all Such data provide a call to action to help design and implement health literacy, liver management and HCC surveillance programs for Indigenous people to help close the liver cancer mortality gap.
Sections du résumé
BACKGROUND
BACKGROUND
Liver disease and hepatocellular carcinoma (HCC) are important contributors to the mortality gap between Indigenous and non-Indigenous Australians. However, there is a lack of population based high quality data assessing the differences in HCC epidemiology and outcomes according to Indigenous status. The aim of this study was therefore to perform a large epidemiological study of HCC investigating differences between Indigenous and non-Indigenous Australians with HCC.
METHODS
METHODS
Study design was a retrospective cohort study. Data linkage methodology was used to link data from cancer registries with hospital separation summaries across three Australian jurisdictions during 2000-2017. Cumulative survival (Kaplan-Meier) and the differences in survival (Multivariable Cox-regression) by Indigenous status were assessed.
FINDINGS
RESULTS
A total of 229 Indigenous and 3587 non-Indigenous HCC cases were included in the analyses. Significant epidemiological differences identified for Indigenous HCC cases included younger age at onset, higher proportion of females, higher rurality, lower socioeconomic status, and higher comorbidity burden (all
INTERPRETATION
CONCLUSIONS
Such data provide a call to action to help design and implement health literacy, liver management and HCC surveillance programs for Indigenous people to help close the liver cancer mortality gap.
Identifiants
pubmed: 34142069
doi: 10.1016/j.eclinm.2021.100919
pii: S2589-5370(21)00199-1
pmc: PMC8187829
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100919Informations de copyright
Crown Copyright © 2021 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Authors disclose the following interests related to this manuscript. Alan Wigg; Gastroenterology Society of Australia Members’ Grant 2019, National Health and Medical Research Council Partnership Grant (GN1170032) 2019, Roche Pharmaceuticals honorarium. Jane Davies; Medical Research Future Fund Investigator Grant, National Health and Medical Research Council Early Career Fellowship, Australian Society for HIV Medicine honorarium. All other authors have nothing to disclose.
Références
JAMA. 1965 Feb 15;191:541-6
pubmed: 14239025
BMJ Open Gastroenterol. 2020 Sep;7(1):
pubmed: 32943463
Hepatol Commun. 2017 Aug 16;1(8):736-747
pubmed: 29404490
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
BMC Public Health. 2014 Nov 28;14:1233
pubmed: 25430502
Med J Aust. 2014 Oct 20;201(8):470-4
pubmed: 25332035
Open Forum Infect Dis. 2019 Nov 03;6(11):ofz469
pubmed: 32864387
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Int J Equity Health. 2020 May 7;19(1):64
pubmed: 32381081
JMIR Res Protoc. 2015 Jun 10;4(2):e70
pubmed: 26063474
Liver Int. 2015 Dec;35(12):2584-94
pubmed: 25900432
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716